HC Wainwright set a $28.00 price objective on Coherus Biosciences (NASDAQ:CHRS) in a research report sent to investors on Monday. The firm currently has a buy rating on the biotechnology company’s stock.
CHRS has been the topic of several other research reports. Zacks Investment Research upgraded Coherus Biosciences from a hold rating to a buy rating and set a $13.00 target price on the stock in a report on Tuesday, October 30th. BidaskClub lowered Coherus Biosciences from a sell rating to a strong sell rating in a report on Tuesday, October 9th. Cowen reiterated a buy rating and set a $45.00 target price on shares of Coherus Biosciences in a report on Friday, November 2nd. Finally, ValuEngine lowered Coherus Biosciences from a strong-buy rating to a buy rating in a report on Friday, September 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Coherus Biosciences currently has an average rating of Buy and an average target price of $27.20.
CHRS opened at $11.93 on Monday. Coherus Biosciences has a 52-week low of $8.05 and a 52-week high of $20.66. The stock has a market cap of $809.10 million, a P/E ratio of -2.66 and a beta of 3.72. The company has a debt-to-equity ratio of 1.66, a quick ratio of 7.79 and a current ratio of 7.79.
In other Coherus Biosciences news, insider Barbara K. Finck sold 1,760 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $18.58, for a total transaction of $32,700.80. Following the transaction, the insider now owns 38,803 shares of the company’s stock, valued at $720,959.74. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director James Healy sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 29th. The stock was sold at an average price of $20.50, for a total value of $512,500.00. The disclosure for this sale can be found here. Insiders have sold 28,520 shares of company stock worth $578,676 in the last quarter. 26.28% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. acquired a new position in Coherus Biosciences during the first quarter worth approximately $115,000. Tower Research Capital LLC TRC acquired a new position in Coherus Biosciences during the second quarter worth approximately $118,000. Hartwell J M Limited Partnership acquired a new position in Coherus Biosciences during the second quarter worth approximately $140,000. Dynamic Technology Lab Private Ltd acquired a new position in Coherus Biosciences during the second quarter worth approximately $193,000. Finally, BlueMountain Capital Management LLC acquired a new position in Coherus Biosciences during the second quarter worth approximately $214,000. 91.25% of the stock is currently owned by hedge funds and other institutional investors.
About Coherus Biosciences
Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.
Recommended Story: The Discount Rate – What You Need to Know
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.